In a frail 87-year-old female with heart failure with preserved ejection fraction, cachexia, and an impacted femoral neck fracture for which surgery is not planned, which beta‑blocker is most appropriate and can enoxaparin be used for venous thromboembolism prophylaxis?

Beta-Blocker Selection and VTE Prophylaxis in Frail HFpEF Patient with Femoral Neck Fracture

Beta-Blocker Recommendation

In this frail 87-year-old woman with HFpEF, cachexia, and non-operative femoral neck fracture management, beta-blockers should be avoided or discontinued if already prescribed. Recent high-quality evidence demonstrates that beta-blockers may be detrimental in frail HFpEF patients, particularly those with Clinical Frailty Scale (CFS) ≥4 1.

Evidence Against Beta-Blockers in This Population

The 2024 PURSUIT-HFpEF registry analysis (1,159 patients, median age 81.4 years) found that beta-blocker use was associated with significantly worse outcomes in frail HFpEF patients (CFS ≥4):

• Adjusted hazard ratio of 1.43 (95% CI 1.10-1.85, p=0.007) for the composite of all-cause death and heart failure readmission 1
• This harmful association was confirmed in propensity-matched analysis (HR 1.42,95% CI 1.05-1.90, p=0.020) 1
• In contrast, beta-blockers showed no significant association with outcomes in non-frail patients (CFS ≤3) 1

Pathophysiologic Rationale

HFpEF patients rely heavily on chronotropic response to maintain cardiac output during stress, as they cannot augment stroke volume due to impaired diastolic filling 2. Beta-blockade further compromises this compensatory mechanism, which is particularly problematic in:

• Frail elderly patients with limited physiologic reserve
• Cachexic patients with reduced metabolic capacity
• Non-ambulatory patients (post-fracture) who need maximal cardiovascular reserve for any activity

Additional Supporting Evidence

• Women with HFpEF showed 75% HF rehospitalization rate with beta-blockers versus 18% without (p<0.001) 3
• Multiple studies show no mortality or hospitalization benefit in HFpEF patients in sinus rhythm without specific indications 4, 5
• The 2001 European guidelines only recommend beta-blockers for HFpEF in the presence of specific indications (atrial fibrillation, post-MI, hypertension requiring rate control) 6

If Beta-Blocker Must Be Continued

If there are compelling indications (recent MI, atrial fibrillation with rapid rate, severe hypertension), consider:

• Carvedilol or bisoprolol are the only beta-blockers with evidence in heart failure populations 6
• Start at lowest doses: carvedilol 3.125 mg twice daily or bisoprolol 1.25 mg once daily 6
• Monitor closely for worsening heart failure symptoms, hypotension (SBP <90 mmHg), or bradycardia 6
• In frail patients, the risks likely outweigh benefits unless there is a specific rate-control indication

---

VTE Prophylaxis with Enoxaparin

Yes, enoxaparin can and should be given for VTE prophylaxis in this patient, with dose adjustment for age, frailty, and renal function.

Recommended Dosing

Enoxaparin 40 mg subcutaneously once daily is the standard prophylactic dose for medical patients with heart failure 7, 8, 9, 10.

Dose Adjustments Required

For this 87-year-old frail patient:

• If creatinine clearance <30 mL/min: reduce to enoxaparin 30 mg once daily 11, 12, 13
• If weight <50 kg (likely given cachexia): consider 30 mg once daily 11, 12
• Monitor for bleeding complications given advanced age and frailty 7

Evidence Supporting Use

The 2022 ACC/AHA Heart Failure Guidelines provide Class I recommendation for VTE prophylaxis in hospitalized HF patients 9:

• Enoxaparin 40 mg subcutaneously once daily reduces radiographically demonstrable venous thrombosis in HF patients with adequate renal function 8, 9
• A 2003 randomized trial specifically in heart failure patients showed enoxaparin was at least as effective as unfractionated heparin (UFH) with fewer adverse events (45.8% vs 53.8%, p=0.044) 10
• Enoxaparin demonstrated significant reduction in VTE (5.5% vs 14.9%) in medical patients with complicated conditions 14

Duration of Prophylaxis

• Continue for the entire duration of immobility from the non-operative femoral neck fracture 7
• Medical patients: prophylaxis should continue for length of hospital stay or until fully ambulatory 7
• Consider extended prophylaxis (up to 4 weeks) given high-risk features: advanced age, immobility from fracture, heart failure, cachexia 7

Alternative if Enoxaparin Contraindicated

If severe renal impairment (CrCl <15 mL/min), active bleeding, or thrombocytopenia:

• Unfractionated heparin 5,000 units subcutaneously every 8-12 hours 7, 8, 14
• Mechanical prophylaxis (intermittent pneumatic compression devices) if anticoagulation absolutely contraindicated 14

Monitoring

• Baseline complete blood count, creatinine clearance, weight
• Monitor for signs of bleeding (particularly given cachexia and frailty)
• In severe renal impairment (CrCl <30 mL/min), consider monitoring anti-Xa levels if using standard dosing, though dose reduction is preferred 11, 12

Critical Pitfall

Do not withhold VTE prophylaxis in non-operative fracture patients—they remain at very high risk for VTE due to immobility, advanced age, and heart failure. The bleeding risk with appropriately dosed enoxaparin is substantially lower than the VTE risk without prophylaxis 7, 9, 10.